CL2009000551A1 - Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound. - Google Patents
Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound.Info
- Publication number
- CL2009000551A1 CL2009000551A1 CL2009000551A CL2009000551A CL2009000551A1 CL 2009000551 A1 CL2009000551 A1 CL 2009000551A1 CL 2009000551 A CL2009000551 A CL 2009000551A CL 2009000551 A CL2009000551 A CL 2009000551A CL 2009000551 A1 CL2009000551 A1 CL 2009000551A1
- Authority
- CL
- Chile
- Prior art keywords
- diabetic
- pyrazin
- pyrrolo
- propan
- eyes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Uso de 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol, o una sal farmacéuticamente aceptable del mismo, para tratar un trastorno relacionado con los ojos como la degeneración macular, retinopatía diabética o edema macular diabético y composición farmacéutica que comprende a dicho compuesto.Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3507308P | 2008-03-10 | 2008-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000551A1 true CL2009000551A1 (en) | 2009-08-21 |
Family
ID=40583469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000551A CL2009000551A1 (en) | 2008-03-10 | 2009-03-09 | Use of 2- [4- (7-ethyl-5h-pyrrolo [2,3-b] pyrazin-6-yl) -phenyl] -propan-2-ol, or a pharmaceutically acceptable salt thereof, to treat a disorder related to the eyes such as macular degeneration, diabetic retinopathy or diabetic macular edema and pharmaceutical composition comprising said compound. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2285378A1 (en) |
JP (1) | JP2011513488A (en) |
KR (1) | KR20110009084A (en) |
CN (1) | CN101965188A (en) |
AR (1) | AR070975A1 (en) |
AU (1) | AU2009223501A1 (en) |
BR (1) | BRPI0909659A2 (en) |
CA (1) | CA2717991A1 (en) |
CL (1) | CL2009000551A1 (en) |
CO (1) | CO6290691A2 (en) |
CR (1) | CR11644A (en) |
DO (1) | DOP2010000266A (en) |
IL (1) | IL207906A0 (en) |
MA (1) | MA32211B1 (en) |
MX (1) | MX2010008308A (en) |
NI (1) | NI201000131A (en) |
NZ (1) | NZ587906A (en) |
RU (1) | RU2010141560A (en) |
SV (1) | SV2010003658A (en) |
TW (1) | TW200950784A (en) |
WO (1) | WO2009114373A1 (en) |
ZA (1) | ZA201005337B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR074776A1 (en) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1263759B1 (en) * | 1999-12-24 | 2010-09-08 | Aventis Pharma Limited | Azaindoles |
CA2400923A1 (en) * | 2000-02-25 | 2001-08-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
EP1928456B1 (en) * | 2005-09-30 | 2015-04-22 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CL2007002617A1 (en) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO. |
-
2009
- 2009-03-05 EP EP09718970A patent/EP2285378A1/en not_active Withdrawn
- 2009-03-05 CA CA2717991A patent/CA2717991A1/en not_active Abandoned
- 2009-03-05 NZ NZ587906A patent/NZ587906A/en not_active IP Right Cessation
- 2009-03-05 KR KR1020107019973A patent/KR20110009084A/en not_active Application Discontinuation
- 2009-03-05 AU AU2009223501A patent/AU2009223501A1/en not_active Abandoned
- 2009-03-05 MX MX2010008308A patent/MX2010008308A/en not_active Application Discontinuation
- 2009-03-05 RU RU2010141560/15A patent/RU2010141560A/en unknown
- 2009-03-05 CN CN2009801075816A patent/CN101965188A/en active Pending
- 2009-03-05 JP JP2010550758A patent/JP2011513488A/en not_active Withdrawn
- 2009-03-05 WO PCT/US2009/036119 patent/WO2009114373A1/en active Application Filing
- 2009-03-05 BR BRPI0909659A patent/BRPI0909659A2/en not_active IP Right Cessation
- 2009-03-09 AR ARP090100835A patent/AR070975A1/en not_active Application Discontinuation
- 2009-03-09 CL CL2009000551A patent/CL2009000551A1/en unknown
- 2009-03-09 TW TW098107567A patent/TW200950784A/en unknown
-
2010
- 2010-07-27 ZA ZA2010/05337A patent/ZA201005337B/en unknown
- 2010-07-29 NI NI201000131A patent/NI201000131A/en unknown
- 2010-08-24 CR CR11644A patent/CR11644A/en not_active Application Discontinuation
- 2010-08-31 IL IL207906A patent/IL207906A0/en unknown
- 2010-09-01 CO CO10108103A patent/CO6290691A2/en not_active Application Discontinuation
- 2010-09-02 DO DO2010000266A patent/DOP2010000266A/en unknown
- 2010-09-07 SV SV2010003658A patent/SV2010003658A/en unknown
- 2010-10-06 MA MA33226A patent/MA32211B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ587906A (en) | 2011-12-22 |
WO2009114373A1 (en) | 2009-09-17 |
MX2010008308A (en) | 2010-08-11 |
AR070975A1 (en) | 2010-05-19 |
CO6290691A2 (en) | 2011-06-20 |
ZA201005337B (en) | 2011-04-28 |
NI201000131A (en) | 2011-09-29 |
JP2011513488A (en) | 2011-04-28 |
AU2009223501A1 (en) | 2009-09-17 |
CN101965188A (en) | 2011-02-02 |
CA2717991A1 (en) | 2009-09-17 |
SV2010003658A (en) | 2011-01-31 |
KR20110009084A (en) | 2011-01-27 |
RU2010141560A (en) | 2012-04-20 |
MA32211B1 (en) | 2011-04-01 |
IL207906A0 (en) | 2010-12-30 |
TW200950784A (en) | 2009-12-16 |
CR11644A (en) | 2010-11-22 |
EP2285378A1 (en) | 2011-02-23 |
BRPI0909659A2 (en) | 2015-09-22 |
DOP2010000266A (en) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7101245A2 (en) | Substituted benzaldehyde compounds and methods for use in increasing tissue oxygenation | |
ECSP12011799A (en) | ESPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME COMPOUNDS | |
AR084691A1 (en) | TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER | |
DOP2014000008A (en) | 4-IMIDAZOPIRIDAZINA-1-IL-BENZAMIDAS AND 4-IMIDAZOTRIAZINA-1-IL-BENZAMIDAS AS BTK INHIBITORS | |
UY35040A (en) | PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED | |
CL2011000973A1 (en) | Compounds derived from pyrazolo [1,5-a] pyrimidine3-cabroxamide; pharmaceutical composition that includes them, and use to treat or reduce the severity of a disease or condition that responds to the inhibition of the activity of a jak kinase. | |
GT201200164A (en) | "NEW SPYROPIPERIDINE COMPOUNDS" | |
ECSP13012611A (en) | PIRAZOL-AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF THE LRRK2 | |
CL2011000170A1 (en) | Solid and stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, titanium oxide and a plasticizer; procedure to stabilize the pharmaceutical composition during a light irradiation. | |
GT201400111A (en) | SUBSTITUTED TRIAZOLOPIRIDINS | |
PE20141406A1 (en) | 4- (8-METHOXY-1 - ((1-METOXYPROPAN-2-IL) -2- (TETRAHYDRO-2H-PYRAN-4-IL) -1H-IMIDAZO [4,5-C] QUINOLIN-7-IL) -3,5-DIMETHYLISOXAZOLE AND ITS USE AS A BROMODOMINIUM INHIBITOR | |
CL2013000481A1 (en) | Method and to improve the efficacy and / or reduce the side effects of a suboptimally administered pharmacotherapy comprising the administration of a substituted hexitol; pharmaceutical composition; pharmaceutical combination; Use to treat proliferative diseases. | |
DOP2010000304A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
UY32461A (en) | 6-METHYL-5- (METHYL-1H-PIRAZOL-5-IL) -N - {[E- (METILSULFONIL) PIRIDIN-2-IL] METHYL -2-OXO-1- [3- (TRIFLUOROMETIL ) PHENYL] -1,2-DIHIDROPIRIDIN-3-CARBOXAMIDA | |
CL2012003075A1 (en) | Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution. | |
BR112015018095A2 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
CL2010001406A1 (en) | Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition. | |
AR085616A1 (en) | INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE | |
UY33277A (en) | SPIRO-TETRACICLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | |
DOP2013000130A (en) | PIRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS THROUGH LP - PLA2 | |
CL2012000319A1 (en) | Use of a pharmaceutical composition comprising treprostinil for the preparation of a medicament for the treatment or prevention of a condition associated with cystic fibrosis. | |
ECSP077323A (en) | NEW DERIVATIVES OF SULFONAMIDE AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
CL2009001298A1 (en) | Compounds derived from n-cyclohexyl-2-phenoxynicotinamide; pharmaceutical composition comprising them; pharmaceutical combination comprising them; and its use to treat a disease mediated by pde4. | |
CL2013000736A1 (en) | Use of ester prodrugs of [3- (1- (1h-imidazol-4-yl) ethyl) -2-methyl-phenyl] methanol to prepare a medicament useful in the treatment of retinal diseases such as wet and dry macular degeneration , and diabetic retinopathy; and use of the composition comprising said compounds. | |
CL2009001077A1 (en) | Polymeric particulate carrier comprising a biological agent in aqueous phase in a hollow lumen; procedure to deliver a protein to the eye; pharmaceutical composition comprising said vehicle; and its use for prophylaxis and treating diseases or disorders of the eye. |